RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SpringWorks Therapeutics Stock

SpringWorks Therapeutics Liabilities 2024

SpringWorks Therapeutics Liabilities

99.57 M USD

Ticker

SWTX

ISIN

US85205L1070

WKN

A2PRLN

In 2024, SpringWorks Therapeutics's total liabilities amounted to 99.57 M USD, a 38.1% difference from the 72.1 M USD total liabilities in the previous year.

SpringWorks Therapeutics Aktienanalyse

What does SpringWorks Therapeutics do?

SpringWorks Therapeutics Inc is a biopharmaceutical company focused on developing innovative drugs for rare and hard-to-treat diseases. The company was founded by Pfizer Inc. in 2017 and is headquartered in Stamford, Connecticut, USA. Since then, it has become one of the leading companies in the industry and works closely with scientists, doctors, and patients to develop better therapies for rare diseases. The business model of SpringWorks Therapeutics Inc is based on identifying and developing drugs for chronic and severe diseases with currently no satisfactory treatment options. The company places great emphasis on the use of new technologies and scientific knowledge to maximize the effectiveness and safety of its drugs. At the same time, it strives to advance product development as quickly and efficiently as possible in order to offer patients better treatment options as soon as possible. An important part of SpringWorks Therapeutics Inc's business model is partnerships and collaborations with other companies and institutions. The company works closely with other biopharmaceutical and biotechnology companies to accelerate its development plans and maximize the potential of its drugs. It also maintains close relationships with research institutes, such as the National Institutes of Health (NIH), to gain the latest scientific knowledge and translate it into new therapies. SpringWorks Therapeutics Inc specializes in the development of drugs for rare and hard-to-treat diseases. The company focuses on four main areas: oncology, neurology, hematology, and pediatrics. In each of these areas, the company has a number of promising programs and products in development. In the oncology field, SpringWorks Therapeutics Inc focuses on developing therapies for patients with rare and hard-to-treat types of cancer. An important program in this area is the development program for Nirogacestat, a gamma-secretase inhibitor. This program has the potential to provide a new treatment option for patients with T-cell lymphoblastic lymphoma (T-ALL) and Alport syndrome. In the neurology field, SpringWorks Therapeutics Inc develops therapies for patients with rare neurological diseases that currently have no satisfactory treatment options. An important focus in this area is the development program for Mirdametinib, a MEK1/2 inhibitor. This program has the potential to offer a new treatment for patients with neurofibromatosis type 1 (NF1). In the hematology field, SpringWorks Therapeutics Inc focuses on developing therapies for patients with rare hematological diseases such as myelofibrosis, chronic myeloid leukemia (CML), and acute myeloid leukemia (AML). An important focus in this area is the development program for Senexin A, an inhibitor of protein methyltransferases. This program has the potential to provide a new therapy for patients with myelofibrosis. In the pediatrics field, SpringWorks Therapeutics Inc develops therapies for children with rare and severe diseases such as nephrotic syndrome and epilepsy. An important program in this area is the development program for PD-0325901, a MEK1/2 inhibitor. This program has the potential to offer a new treatment for patients with nephrotic syndrome. Overall, SpringWorks Therapeutics Inc has an impressive pipeline of promising development programs that have the potential to improve the lives of patients with rare and hard-to-treat diseases. Through its close collaboration with other companies, research institutes, and patient organizations, the company is able to effectively and efficiently implement its development plans and thus create better treatment options for patients around the world. SpringWorks Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing SpringWorks Therapeutics's Liabilities

SpringWorks Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating SpringWorks Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing SpringWorks Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

SpringWorks Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in SpringWorks Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about SpringWorks Therapeutics stock

What is the level of liabilities of SpringWorks Therapeutics this year?

SpringWorks Therapeutics has a debt balance of 99.57 M USD this year.

What were the liabilities of SpringWorks Therapeutics compared to the previous year?

The liabilities of SpringWorks Therapeutics have increased by 38.1% increased compared to the previous year.

What are the consequences of high debt for investors of SpringWorks Therapeutics?

High liabilities can pose a risk for investors of SpringWorks Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in SpringWorks Therapeutics?

Low liabilities mean that SpringWorks Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of SpringWorks Therapeutics affect the company?

An increase in liabilities of SpringWorks Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of SpringWorks Therapeutics affect the company?

A decrease in the liabilities of SpringWorks Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of SpringWorks Therapeutics?

Some factors that can influence the liabilities of SpringWorks Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of SpringWorks Therapeutics so important for investors?

The liabilities of SpringWorks Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can SpringWorks Therapeutics take to modify the liabilities?

To change its liabilities, SpringWorks Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does SpringWorks Therapeutics pay?

Over the past 12 months, SpringWorks Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SpringWorks Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of SpringWorks Therapeutics?

The current dividend yield of SpringWorks Therapeutics is .

When does SpringWorks Therapeutics pay dividends?

SpringWorks Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SpringWorks Therapeutics?

SpringWorks Therapeutics paid dividends every year for the past 0 years.

What is the dividend of SpringWorks Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is SpringWorks Therapeutics located?

SpringWorks Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von SpringWorks Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SpringWorks Therapeutics from 11/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/3/2024.

When did SpringWorks Therapeutics pay the last dividend?

The last dividend was paid out on 11/3/2024.

What was the dividend of SpringWorks Therapeutics in the year 2023?

In the year 2023, SpringWorks Therapeutics distributed 0 USD as dividends.

In which currency does SpringWorks Therapeutics pay out the dividend?

The dividends of SpringWorks Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SpringWorks Therapeutics

Our stock analysis for SpringWorks Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SpringWorks Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.